133 related articles for article (PubMed ID: 38558804)
21. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
[TBL] [Abstract][Full Text] [Related]
22. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.
Ni Y; Gao L; Lu Y; Ye S; Zhou L; Qian W; Liang A; Li P
Front Immunol; 2022; 13():982346. PubMed ID: 36119029
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Yuen MF; Agarwal K; Ma X; Nguyen TT; Schiff ER; Hann HL; Dieterich DT; Nahass RG; Park JS; Chan S; Han SB; Gane EJ; Bennett M; Alves K; Evanchik M; Yan R; Huang Q; Lopatin U; Colonno R; Ma J; Knox SJ; Stamm LM; Bonacini M; Jacobson IM; Ayoub WS; Weilert F; Ravendhran N; Ramji A; Kwo PY; Elkhashab M; Hassanein T; Bae HS; Lalezari JP; Fung SK; Sulkowski MS
J Hepatol; 2022 Sep; 77(3):642-652. PubMed ID: 35460726
[TBL] [Abstract][Full Text] [Related]
26. Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B.
Li MH; Lu Y; Zhang L; Wang XY; Ran CP; Hao HX; Zhang D; Qu XJ; Shen G; Wu SL; Cao WH; Qi TL; Liu RY; Hu LP; Chang M; Hua WH; Liu SA; Wan G; Xie Y
Chin Med J (Engl); 2018 Aug; 131(15):1813-1818. PubMed ID: 30058578
[TBL] [Abstract][Full Text] [Related]
27. [Observation of PD-1
He J; Yao YQ; Xia RX; Qiu TJ; Long L; Wang Y; Jiang Y
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):316-322. PubMed ID: 35462489
[No Abstract] [Full Text] [Related]
28. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation.
Fang J; Li W; Tan M; Chen W; Zhang C; Wang W; Xu Q; Guo X
Int Urol Nephrol; 2018 Sep; 50(9):1653-1660. PubMed ID: 29644524
[TBL] [Abstract][Full Text] [Related]
29. [Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].
Pan JL; Luo H; Zhang XX; Han YF; Chen HY; Zeng Z; Xu XY
Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):16-21. PubMed ID: 38320786
[No Abstract] [Full Text] [Related]
30. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
[TBL] [Abstract][Full Text] [Related]
31. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
32. [Effects of programmed death receptor-1 antibody in patients with hepatitis B-associated liver cancer].
Yu YY; Wang SY; Tu B; Shen YJ; Qiu Q; Luan JQ; Wang FS; Meng FP; Shi M
Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):659-665. PubMed ID: 34371536
[No Abstract] [Full Text] [Related]
33. [Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province].
Zhang BF; Cheng ML; Zhang Q; Zhao XK; Yu L; Yang J; Deng KS; Zhang LS; Wang J; Hu YX
Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):945-950. PubMed ID: 30669789
[No Abstract] [Full Text] [Related]
34. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
35. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus.
Eke AC; Eleje GU; Eke UA; Xia Y; Liu J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008545. PubMed ID: 28188612
[TBL] [Abstract][Full Text] [Related]
37. Management of HBV reactivation in non-oncological patients.
Pisaturo M; Di Caprio G; Calò F; Portunato F; Martini S; Coppola N
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):611-624. PubMed ID: 30058401
[TBL] [Abstract][Full Text] [Related]
38. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
[TBL] [Abstract][Full Text] [Related]
39. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
40. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
